Medicus Pharma Ltd (MDCX)

$0.31 -0.02 (-5.18%)
Market Cap 13.07M
Revenue (ttm) 0.00
Net Income (ttm) -35.46M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,262,800
Avg Vol 7,408,650
Day's Range N/A - N/A
Shares Out 39.36M
Stochastic %K 16%
Beta 1.16
Analysts Strong Sell
Price Target $7.50

Company Profile

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. Medicus Pharma Ltd. has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to M...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 610 540 7515
Address:
300 Conshohocken State Road, Suite 200, Conshohocken, United States
Cullousus
Cullousus Apr. 25 at 5:50 PM
$MDCX they are waiting on the CSR report to fully show the ability of the medicines ability to treat the most common skin cancer without invasive surgery and also helps patients who are stuck waiting in long waiting lines to help. The stocks float is still small so the price is easily manipulated.
0 · Reply
focafoca99
focafoca99 Apr. 25 at 5:56 AM
$MDCX expanded its equity distribution agreement through an amendment that increased the aggregate offering amount.
0 · Reply
miwails
miwails Apr. 24 at 11:51 PM
$CXAI oh btw @dumpcxaibuymdcx - $MDCX down 12% :/
1 · Reply
woodruffn2
woodruffn2 Apr. 24 at 11:29 PM
$MDCX any news out whats going on this company has strong potential
0 · Reply
razorsedge4343
razorsedge4343 Apr. 24 at 11:12 PM
$MDCX The flight
1 · Reply
DrStonkenstein
DrStonkenstein Apr. 24 at 10:53 PM
$MDCX Failure to satisfy, you have D-180 starting Monday..
1 · Reply
Cullousus
Cullousus Apr. 24 at 10:32 PM
$MDCX history often rhymes but never repeats.
0 · Reply
Cullousus
Cullousus Apr. 24 at 10:26 PM
$MDCX naked shorties best becareful
0 · Reply
Cullousus
Cullousus Apr. 24 at 10:09 PM
$MDCX the delay signals this is the CSR 8-k information is coming
0 · Reply
Cullousus
Cullousus Apr. 24 at 9:59 PM
$MDCX
1 · Reply
Latest News on MDCX
Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Apr 17, 2026, 7:30 AM EDT - 8 days ago

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression

Apr 15, 2026, 7:30 AM EDT - 10 days ago

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression

EXCLUSIVE: Penny Stock Medicus Pharma Findings Support Potential In Women's Health Pipeline

Apr 15, 2026, 7:16 AM EDT - 10 days ago

EXCLUSIVE: Penny Stock Medicus Pharma Findings Support Potential In Women's Health Pipeline

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

Apr 6, 2026, 7:30 AM EDT - 19 days ago

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

EXCLUSIVE: Medicus Pharma Refines Trial Design To Cut Costs, Accelerate Development For Enlarged Prostate Patients

Apr 6, 2026, 7:16 AM EDT - 19 days ago

EXCLUSIVE: Medicus Pharma Refines Trial Design To Cut Costs, Accelerate Development For Enlarged Prostate Patients

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

Apr 1, 2026, 7:30 AM EDT - 24 days ago

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

Mar 30, 2026, 7:30 AM EDT - 26 days ago

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Mar 26, 2026, 7:30 AM EDT - 4 weeks ago

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update

Mar 25, 2026, 4:30 PM EDT - 4 weeks ago

Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

Mar 18, 2026, 7:30 AM EDT - 5 weeks ago

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Mar 16, 2026, 7:30 AM EDT - 5 weeks ago

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum

Mar 10, 2026, 7:30 AM EDT - 6 weeks ago

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

Mar 9, 2026, 7:30 AM EDT - 6 weeks ago

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

Medicus Pharma Stock Swings After Skin Cancer Treatment Results

Mar 5, 2026, 9:13 AM EST - 7 weeks ago

Medicus Pharma Stock Swings After Skin Cancer Treatment Results

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

Mar 5, 2026, 7:30 AM EST - 7 weeks ago

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

Medicus Pharma To Participate in the 38th Annual Roth Conference

Mar 3, 2026, 7:30 AM EST - 7 weeks ago

Medicus Pharma To Participate in the 38th Annual Roth Conference

Medicus Pharma on Bloomberg World

Feb 12, 2026, 7:30 AM EST - 2 months ago

Medicus Pharma on Bloomberg World

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Feb 10, 2026, 7:30 AM EST - 2 months ago

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

Jan 23, 2026, 7:30 AM EST - 3 months ago

Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Jan 22, 2026, 7:30 AM EST - 3 months ago

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

Jan 20, 2026, 7:30 AM EST - 3 months ago

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Jan 12, 2026, 7:30 AM EST - 3 months ago

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

Jan 5, 2026, 7:30 AM EST - 3 months ago

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Dec 22, 2025, 7:30 AM EST - 4 months ago

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Dec 15, 2025, 7:30 AM EST - 4 months ago

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Dec 5, 2025, 3:20 PM EST - 5 months ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Dec 1, 2025, 8:00 AM EST - 5 months ago

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Nov 24, 2025, 8:00 AM EST - 5 months ago

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 17, 2025, 7:30 AM EST - 5 months ago

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Nov 14, 2025, 5:00 PM EST - 5 months ago

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 13, 2025, 7:30 AM EST - 5 months ago

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Oct 22, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Oct 14, 2025, 8:07 AM EDT - 6 months ago

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Oct 13, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Oct 7, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Sep 29, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Sep 24, 2025, 9:26 AM EDT - 7 months ago

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Medicus Pharma Ltd. To Present at Brookline Capital Markets

Sep 24, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. To Present at Brookline Capital Markets

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Sep 18, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Sep 8, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Sep 2, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

Aug 21, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Aug 4, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Jul 23, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Jul 21, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

Jul 8, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

Jun 30, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer

Jun 23, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer

Cullousus
Cullousus Apr. 25 at 5:50 PM
$MDCX they are waiting on the CSR report to fully show the ability of the medicines ability to treat the most common skin cancer without invasive surgery and also helps patients who are stuck waiting in long waiting lines to help. The stocks float is still small so the price is easily manipulated.
0 · Reply
focafoca99
focafoca99 Apr. 25 at 5:56 AM
$MDCX expanded its equity distribution agreement through an amendment that increased the aggregate offering amount.
0 · Reply
miwails
miwails Apr. 24 at 11:51 PM
$CXAI oh btw @dumpcxaibuymdcx - $MDCX down 12% :/
1 · Reply
woodruffn2
woodruffn2 Apr. 24 at 11:29 PM
$MDCX any news out whats going on this company has strong potential
0 · Reply
razorsedge4343
razorsedge4343 Apr. 24 at 11:12 PM
$MDCX The flight
1 · Reply
DrStonkenstein
DrStonkenstein Apr. 24 at 10:53 PM
$MDCX Failure to satisfy, you have D-180 starting Monday..
1 · Reply
Cullousus
Cullousus Apr. 24 at 10:32 PM
$MDCX history often rhymes but never repeats.
0 · Reply
Cullousus
Cullousus Apr. 24 at 10:26 PM
$MDCX naked shorties best becareful
0 · Reply
Cullousus
Cullousus Apr. 24 at 10:09 PM
$MDCX the delay signals this is the CSR 8-k information is coming
0 · Reply
Cullousus
Cullousus Apr. 24 at 9:59 PM
$MDCX
1 · Reply
xploder05
xploder05 Apr. 24 at 9:57 PM
$MDCX whoa, seriously, a lot of unhinged people here! Its a .29 stock, lmaooooo. Its a speculative play. Why so serious.?
0 · Reply
2TrustHim
2TrustHim Apr. 24 at 9:53 PM
$MDCX How Stupid Do They Think We Are That A Video News Clip Promoting Nothing Will Move It To the lying Advisers Making Up That Price Target Last Year?
0 · Reply
2TrustHim
2TrustHim Apr. 24 at 9:48 PM
$MDCX Any Lawsuits coming For these phonies???
0 · Reply
2TrustHim
2TrustHim Apr. 24 at 8:50 PM
$MDCX WHEN $27.00 😃
1 · Reply
dawsondesign
dawsondesign Apr. 24 at 8:01 PM
$MDCX bids on deck, let’s see it
0 · Reply
Cullousus
Cullousus Apr. 24 at 7:20 PM
$MDCX inverted head n shoulders forming on daily. Need the volume to hammer through.
0 · Reply
Cullousus
Cullousus Apr. 24 at 6:23 PM
$MDCX higher lows.
0 · Reply
Cullousus
Cullousus Apr. 24 at 6:23 PM
$MDCX we didn't break below .3 thats bullish even when we got a pr saying potential dilution people held on because they know what they hold. The real move is coming it just takes time for the report to come out.
1 · Reply
dawsondesign
dawsondesign Apr. 24 at 6:09 PM
$MDCX please just be the dip and rip. I have held this for 2 weeks at .32
0 · Reply
Cullousus
Cullousus Apr. 24 at 5:03 PM
$MDCX
0 · Reply
Cullousus
Cullousus Apr. 24 at 5:03 PM
$MDCX its a win win win... retail wins the company wins and the patients who can be saved from being cut open and getting permanent scars win.
0 · Reply
Cullousus
Cullousus Apr. 24 at 4:22 PM
$MDCX the doctor who actually ran the trials had good things to say.
0 · Reply